2018年6月1日
Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseases
Drug Discovery Today
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 23
- 号
- 6
- 開始ページ
- 1305
- 終了ページ
- 1311
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.drudis.2018.05.009
- 出版者・発行元
- Elsevier Ltd
Given the paradigm of anti-insulin resistance in therapies for metabolic syndrome, there has been considerable interest in adiponectin (APN), an adipocyte-derived sensitizer of insulin receptor signaling. In contrast to hypoadiponectinemia in metabolic syndrome, evidence suggests that Alzheimer's disease (AD) and other diseases, including chronic heart failure (CHF) and chronic kidney disease (CKD), are characterized by hyperadiponectinemia as well as the APN/obesity paradoxes, indicating that a decrease in APN might also be beneficial for these diseases. Thus, distinct from metabolic syndrome, it is anticipated that APN receptor antagonists rather than agonists might be effective in therapy for some chronic diseases.
- ID情報
-
- DOI : 10.1016/j.drudis.2018.05.009
- ISSN : 1878-5832
- ISSN : 1359-6446
- SCOPUS ID : 85047187801